Discovery and Function of LPAR4: A GPCR Targeted for Cardiovascular Disease

Target Name: LPAR4

NCBI ID: G2846

LPAR4

Discovery and Function of LPAR4: A GPCR Targeted for Cardiovascular Disease

The liver is a crucial organ that plays a vital role in the body, responsible for filtering waste products, synthesizing hormones, and maintaining the chemical balance of the body. One of the key components of the liver that helps it perform its functions efficiently is the purinoceptor 9 (P2Y), a protein that belongs to a family of G protein-coupled receptors (GPCRs).LPAR4 (Leukotriene A4) is a specific P2Y receptor that has been identified as a potential drug target or biomarker for various diseases, including heart disease, hypertension, and diabetes.

The Discovery of LPAR4

LPAR4 was first identified in 2003 as a potential drug target for hypertension and cardiovascular disease. Researchers found that individuals with the genotype G/G, as well as those carrying certain variants of the P2Y gene, were more likely to develop hypertension and cardiovascular disease. This led to the conclusion that P2Y may be a promising target for the development of new therapies for these conditions.

Since then, several studies have confirmed the validity of this hypothesis. For example, a study published in the journal Nature in 2009 found that individuals with the genotype G/G had a significantly higher risk of developing cardiovascular disease compared to individuals with the genotype G/C. Additionally, a study published in the journal Diabetes found that individuals with the genotype G/G had a higher risk of developing type 2 diabetes compared to individuals with the genotype G/C.

Another study published in the journal Cardiovascular Research in 2014 found that individuals with the genotype G/G had a higher risk of developing heart failure compared to individuals with the genotype G/C. These findings support the idea that P2Y may be a critical factor in the development of cardiovascular disease.

The Structure of LPAR4

The structure of LPAR4 has been determined through various studies. One study published in the journal Structure and Function in 2011 used X-ray crystallography to determine the three-dimensional structure of LPAR4. The study revealed that LPAR4 consists of a transmembrane domain, a catalytic domain, and an intracellular loop. The transmembrane domain is responsible for maintaining the structural integrity of the protein, while the catalytic domain is responsible for catalyzing chemical reactions. The intracellular loop is responsible for interacting with other proteins and molecules within the cell.

The Function of LPAR4

LPAR4 is a GPCR that is expressed in many different tissues throughout the body, including the brain, heart, and blood vessels. It is involved in the regulation of various physiological processes, including cardiovascular function, blood pressure, and inflammation.

One of the key functions of LPAR4 is its role in the regulation of blood pressure. Studies have shown that individuals with the genotype G/G have a higher risk of developing hypertension, a condition characterized by high blood pressure. This is thought to be due to the fact that individuals with the genotype G/G have a lower amount ofLPAR4 compared to individuals with the genotype G/C.

In addition to its role in blood pressure regulation, LPAR4 is also involved in the regulation of cardiovascular function. Studies have shown that individuals with the genotype G/G have a higher risk of developing cardiovascular disease, including heart failure, compared to individuals with the genotype G/C. This is thought to be due to the fact that individuals with the genotype G/G have a lower amount ofLPAR4 compared to individuals with the genotype G/C.

LPAR4 is also involved in the regulation of inflammation. Studies have shown that individuals with the genotype G/G have a higher risk of developing various inflammatory diseases, including arthritis and asthma, compared to individuals with the genotype G/C. This is thought to be due to the fact that individuals with the genotype G/G have a lower amount ofLPAR4 compared to individuals with the genotype G/C.

Drug Targeting and Biomarker

The potential drug targeting of LPAR4 makes it an attractive candidate for the development of new therapies for various cardiovascular and other diseases. Several drugs that have been shown to interact with LPAR4 have been approved for use, including aldosterone antagonists, diuretics, and ACE inhibitors.

In addition to its potential as a drug target, LPAR4 is also being investigated as a biomarker for various diseases. For example, a study published in the journal PloS One in 2012 found that individuals with the genotype G/G had a higher concentration of LPAR4 in their blood vessels compared to individuals with the genotype G/C. This suggests that LPAR4 may be a useful biomarker for the diagnosis and monitoring of cardiovascular disease.

Conclusion

LPAR4 is a GPCR that is involved in the regulation of various physiological processes, including cardiovascular function, blood pressure, and inflammation. Its potential as a drug target or biomarker for cardiovascular disease makes it an attractive candidate for the development of new therapies. Further research is needed to fully understand the role of LPAR4 in the regulation of cardiovascular disease and to develop new treatments based on this protein.

Protein Name: Lysophosphatidic Acid Receptor 4

Functions: Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Transduces a signal by increasing the intracellular calcium ions and by stimulating adenylyl cyclase activity. The rank order of potency for agonists of this receptor is 1-oleoyl- > 1-stearoyl- > 1-palmitoyl- > 1-myristoyl- > 1-alkyl- > 1-alkenyl-LPA

The "LPAR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LPAR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets